Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TACR3 | P29371 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 3/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24062095 | 0.86 | NAMPT (0.47) | HPGDNAMPTKDM4EPOLB | |
| SCHEMBL20214653 | 0.84 | GRM5 (0.50) | HPGDNAMPTPKMKDM4E | |
| SCHEMBL22916015 | 0.84 | POLB (0.57) | HPGDNAMPTKDM4EPOLBTSHR | |
| SCHEMBL24062105 | 0.84 | NAMPT (0.44) | HPGDNAMPTKDM4EP2RX7POLB | |
| Oxalic Acid SCHEMBL6423881 | 0.83 | NAMPT (0.44) | HPGDNAMPTKDM4EPOLB | |
| SCHEMBL22915886 | 0.82 | NAMPT (0.51) | HPGDNAMPTKDM4EPOLBMAPK14 | |
| SCHEMBL22915948 | 0.81 | NAMPT (0.60) | NAMPTKDM4E | |
| SCHEMBL22915970 | 0.81 | POLB (0.55) | HPGDNAMPTPKMKDM4ETACR3 | |
| SCHEMBL22915890 | 0.81 | KDM4E (0.47) | HPGDNAMPTKDM4EMTHFD2 | |
| SCHEMBL22915936 | 0.80 | HPGD (0.53) | HPGDNAMPTPKMKDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186572-B2 | Bacterial glutaminyl cyclases and inhibitors thereof for use in the treatment of periodontitis | FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) | 2021-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11186572-B2 | Bacterial glutaminyl cyclases and inhibitors thereof for use in the treatment of periodontitis | GMPS, QPCT, GLS | HPGD 606/4885NAMPT 1158/4885PKM 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.